| 1. |
- Song, Young Eun, et al.
(författare)
-
Increased CODH activity in a bioelectrochemical system improves microbial electrosynthesis with CO
- 2020
-
Ingår i: Sustainable Energy and Fuels. - : Royal Society of Chemistry (RSC). - 2398-4902. ; 4:12, s. 5952-5957
-
Tidskriftsartikel (refereegranskat)abstract
- Biological CO conversion has attracted considerable interest because of the demand for syngas valorization and the simultaneous treatment of toxic components in industrial flue gases. The oxidation of CO can produce additional reducing equivalents in the form of electrons and protons by the water gas shift reaction (WGSR) via carbon monoxide dehydrogenase (CODH). Such reducing energy decreases the thermodynamic and kinetic barriers of the bioconversion of gaseous carbon and increases the product yield. This study examined the effects of yeast extract, leading to increased CODH activity, on electrosynthesis with CO in an electrode-assisted bioelectrochemical system. The specific CODH activity was significantly higher (90.2 +/- 2.6 nmol mg(-1) min(-1)) when the yeast extract was added compared to electrosynthesis without the yeast extract (11.8 +/- 1.1 nmol mg(-1) min(-1)). After 483 h, the levels of acetate and volatile fatty acids (VFAs) were 3.5 and 0.8 g L-1, respectively, when the CODH activity was higher, but only 1.3 and 0.2 g L-1, respectively, in cultures with lower CODH activity. The maximum coulombic efficiency of electrosynthesis with CO was two times higher than the conventional electrosynthesis using CO2 with higher CODH activity, whereas it was only half with lower CODH activity. The results show that an increase in CODH activity can be an efficient approach to enhance the electrosynthesis of CO.
|
|
| 2. |
- Armand, Philippe, et al.
(författare)
-
Five-year follow-up of KEYNOTE-087 : pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
- 2023
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 142:10, s. 878-886
-
Tidskriftsartikel (refereegranskat)abstract
- Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durability and outcome of patients who receive a second course after treatment discontinuation after complete response (CR) remain of clinical interest. We present KEYNOTE-087 data after >5 years of median follow-up. Patients with R/R cHL and progressive disease (PD) after autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV; cohort 1), salvage chemotherapy and BV without ASCT (cohort 2), or ASCT without subsequent BV (cohort 3), received pembrolizumab for <= 2 years. Patients in CR who discontinued treatment and subsequently experienced PD were eligible for second-course pembrolizumab. Primary end points were the objective response rate (ORR) using blinded central review and safety. The median follow-up was 63.7 months. ORR was 71.4% (95% confidence interval [CI], 64.8-77.4; CR, 27.6%; partial response, 43.8%). Median duration of response (DOR) was 16.6 months; median progression-free survival was 13.7 months. A quarter of responders, including half of complete responders, maintained a response for >= 4 years. Median overall survival was not achieved. Among 20 patients receiving second-course pembrolizumab, ORR for 19 evaluable patients was 73.7% (95% CI, 48.8-90.8); median DOR was 15.2 months. Any-grade treatment-related adverse events occurred in 72.9% of patients and grade 3 or 4 adverse events occurred in 12.9% of patients; no treatment-related deaths occurred. Single-agent pembrolizumab can induce durable responses, particularly in patients achieving CR. Second-course pembrolizumab frequently reinduced sustained responses after relapse from initial CR.
|
|
| 3. |
- Chen, Robert, et al.
(författare)
-
Pembrolizumab in relapsed or refractory Hodgkin lymphoma : 2-year follow-up of KEYNOTE-087
- 2019
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 134:14, s. 1144-1153
-
Tidskriftsartikel (refereegranskat)abstract
- Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9% (95% CI, 65.3-77.9), the complete response rate (CRR) was 27.6%, and the partial response (PR) rate was 44.3%. Median duration of response was 16.5months (range, 0.0+ to 27.0+ [+, no progressive disease at last assessment]) in all patients, 22.1months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95% CI, 12.0-22.1) for patients with PR and 10.9 months (95% CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9%) patients; grades 3 and 4 occurred in 25 (12.0%) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL.
|
|
